A three-drug combination treatment for the blood cancer multiple myeloma
compares favorably to the best established therapy for newly diagnosed
patients, according to a multi-center study led by Andrzej Jakubowiak,
MD, PhD, professor of medicine and director of the multiple myeloma
program at the University of
Chicago Medical Center.
The combination includes an
investigational medicine called carfilzomib
combined with two standard medications: lenalidomide, an analogue of
thalidomide, and low-dose dexamethasone, an anti-inflammatory with
anti-cancer properties.
"This combination appears to deliver everything we expected and more," said Jakubowiak, who came to the University of Chicago this fall from the University of Michigan. "We have seen excellent efficacy — the best reported to date — without the neurotoxicity that has been problematic with other drug combinations."
Ref : http://www.uchospitals.edu/news/2011/20111206-myeloma.html